Section Arrow
NBTX.NASDAQ
- Nanobiotix SA
Quotes are at least 15-min delayed:2026/07/24 08:02 EDT
Pre Market
Last
 40.04
+0.49 (+1.24%)
Bid
40.04
Ask
40.31
High 40.29 
Low 40.02872 
Volume 10.20K 
Regular Hours (Closed)
Last
 39.55
-0.83 (-2.06%)
Day High 
40.63 
Prev. Close
40.38 
1-M High
42.9199 
Volume 
153.06K 
Bid
40.04
Ask
40.31
Day Low
38 
Open
39.5 
1-M Low
33.1212 
Market Cap 
2.05B 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 39.06 
20-SMA 38.28 
50-SMA 39.65 
52-W High 57.14 
52-W Low 6.09 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.50/0.72
Enterprise Value
2.14B
Balance Sheet
Book Value Per Share
-1.89
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
29.64M
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
CLDICalidi Biotherapeutics0.105-0.0006-0.57%-- 
Pre Market 0.1091 +0.0041 +3.90%
RXRXRecursion Pharmaceuticals3.01+0.03+1.01%-- 
Pre Market 3.04 +0.03 +1.00%
GOSSGossamer Bio0.1425-0.0021-1.45%-- 
Pre Market 0.1413 -0.0012 -0.84%
IOVAIovance Biotherapeutics5.13-0.04-0.77%-- 
Pre Market 5.11 -0.02 -0.39%
ATAIAtaiBeckley Inc7.17-0.01-0.14%-- 
Pre Market 7.17 0 0.00%
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Nanobiotix SA is a late-stage clinical biotechnology company focused on re-inventing medicine by building new therapies atom by atom, developing widely applicable, first-in-class, physics-based nanotherapeutics to transform treatment outcomes and expand life for millions of patients. The objective of this physics-based approach is to allow nanoparticles to be combined with other drugs or therapeutic modalities and to integrate seamlessly into clinical practice without addingburden for the patient, healthcare provider, or healthcare system. It has three platforms Nanoradioenhancer platform: Nanoprimer platform: and Neurological disease platform. It has one segment, which is the research and development of product candidates that use proprietary nanotechnology to transform cancer treatment.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.